US 12,006,344 B2
MIC-1 compounds and use thereof
Xujia Zhang, Beijing (CN); Xiang Gao, Beijing (CN); Hongtao Guan, Beijing (CN); Henning Thoegersen, Farum (DK); Kristian Sass-oerum, Koebenhavn (DK); Lars Fogh Iversen, Holte (DK); Per Noergaard, Humlebaek (DK); Sebastian Beck Joergensen, Virum (DK); Kristian Tage Hansen, Slangerup (DK); and Yi Wang, Beijing (CN)
Assigned to Novo Nordisk A/S, Bagsvaerd (DK)
Filed by Novo Nordisk A/S, Bagsvaerd (DK)
Filed on Dec. 19, 2022, as Appl. No. 18/083,811.
Application 18/083,811 is a continuation of application No. 17/194,908, filed on Mar. 8, 2021, abandoned.
Application 17/194,908 is a continuation of application No. 16/303,516, abandoned, previously published as PCT/EP2017/062583, filed on May 24, 2017.
Claims priority of application No. PCT/CN2016/083104 (WO), filed on May 24, 2016; and application No. PCT/CN2016/103574 (WO), filed on Oct. 27, 2016.
Prior Publication US 2023/0212245 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/475 (2006.01); A61K 38/00 (2006.01); A61K 38/27 (2006.01); A61P 3/04 (2006.01)
CPC C07K 14/475 (2013.01) [A61K 38/00 (2013.01); A61K 38/27 (2013.01); A61P 3/04 (2018.01); C07K 2319/31 (2013.01)] 1 Claim
 
1. A MIC-1 compound comprising a MIC-1 polypeptide and an N-terminal amino acid extension, wherein the compound comprises an amino acid sequence according to SEQ ID NO: 100, 104, 106, 107, 108, 109, 111, 112, 113, 114, 115, 116, 117 or 164.